The research focus of Xiaojiang Cui, PhD, is to decipher biochemical and signaling mechanisms of cancer metastasis and therapeutic resistance as well as utilize these mechanisms to identify potential targets for therapeutic interventions. He is working to develop effective anticancer therapies based on these targets.

• Breast Cancer Program
• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Department of Surgery
• Cancer
• Obstetrics and Gynecology
• Surgery

• Editorial Board Member: Journal of Analytical Oncology, Current
• Presentation Award, Annual Dan L. Duncan Cancer Center Retreat, Baylor College of Medicine, 2006
• Breast Cancer SPORE Career Development Award, National Cancer Institute, 2004
• First Place Abstract, Annual Dan L. Duncan Cancer Center Retreat, Baylor College of Medicine, 2003
• Postdoctoral Training Award, U.S. Department of Defense Breast Cancer Research Program, 2001

• Qu Y, Wang J, Ray PS, Guo H, Huang J, Shin-Sim M, Bukoye BA, Liu B, Lee AV, Lin X, Huang P, Martens JW, Giuliano AE, Zhang N, Cheng NH, Cui X. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. J Clin Invest. 2010;121(1):212-225.
• Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon DS, Walter MA, Martens JW, Richardson AL, Giuliano AE, Cui X. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 2010;70(10):3870-3876.
• Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X. Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res. 2010;8(2):266-277.